Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PNCA3
MCID: PNC095
MIFTS: 28

Pancreatic Cancer 3 (PNCA3)

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Pancreatic Cancer 3

About this section

MalaCards integrated aliases for Pancreatic Cancer 3:

Name: Pancreatic Cancer 3 56 73 29 6
Pancreatic Cancer, Susceptibility to, 3 56 13
Pnca3 56 73
Cancer, Pancreatic, Susceptibility to, Type 3 39

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases
Anatomical: Endocrine diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 613348
MeSH 43 D010190
MedGen 41 C3150547
Sources

Summaries for Pancreatic Cancer 3

About this section
UniProtKB/Swiss-Prot : 73 Pancreatic cancer 3: A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

MalaCards based summary : Pancreatic Cancer 3, also known as pancreatic cancer, susceptibility to, 3, is related to pancreatic cancer and zollinger-ellison syndrome. An important gene associated with Pancreatic Cancer 3 is PALB2 (Partner And Localizer Of BRCA2). The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and breast.

More information from OMIM: 613348
Sources

Related Diseases for Pancreatic Cancer 3

About this section

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1 Pancreatic Cancer 2
Pancreatic Cancer 3 Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer 3 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 9.8
2 zollinger-ellison syndrome 9.8

Sources

Symptoms & Phenotypes for Pancreatic Cancer 3

About this section

Clinical features from OMIM:

613348
Sources

Drugs & Therapeutics for Pancreatic Cancer 3

About this section

Drugs for Pancreatic Cancer 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
3
Pancrelipase Approved, Investigational Phase 2 53608-75-6
4
Fluorouracil Approved Phase 2 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
6
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
7
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
8 Immunologic Factors Phase 2
9 Anti-Infective Agents Phase 2
10 Albumin-Bound Paclitaxel Phase 2
11 Tubulin Modulators Phase 2
12 Immunosuppressive Agents Phase 2
13 Antiviral Agents Phase 2
14 Antimetabolites Phase 2
15 Antimitotic Agents Phase 2
16 pancreatin Phase 2
17 Mitogens Phase 2
18 Antineoplastic Agents, Immunological Phase 2
19
Sulindac Approved, Investigational Phase 1 38194-50-2 1548887 5352
20
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
21 Protein Kinase Inhibitors Phase 1
22 Analgesics, Non-Narcotic Phase 1
23 Analgesics Phase 1
24 Cyclooxygenase Inhibitors Phase 1
25 Antirheumatic Agents Phase 1
26 Anti-Inflammatory Agents Phase 1
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1
28
Levoleucovorin Approved, Investigational Early Phase 1 68538-85-2
29
leucovorin Approved Early Phase 1 58-05-9 6006 143
30
Oxaliplatin Approved, Investigational Early Phase 1 61825-94-3 43805 6857599 5310940 9887054
31
Folic acid Approved, Nutraceutical, Vet_approved Early Phase 1 59-30-3 6037
32 Folate Early Phase 1
33 topoisomerase I inhibitors Early Phase 1
34 Folfirinox Early Phase 1
35 Vitamin B9 Early Phase 1
36 Calcium, Dietary Early Phase 1
37
Calcium Nutraceutical Early Phase 1 7440-70-2 271

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer Completed NCT01298011 Phase 2 Gemcitabine and Abraxane
2 A Randomized, Placebo-controlled, Blinded Phase II Study of Huachansu & Gemcitabine in Pancreatic Cancer Completed NCT00837239 Phase 2 Gemcitabine;HuaChanSu;Placebo
3 Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System Recruiting NCT03185988 Phase 2 chemotherapy in combination with trastuzumab for arm1;chemotherapy in combination with trastuzumab for arm2;chemotherapy in combination with trastuzumab for arm3;chemotherapy in combination with trastuzumab for arm4
4 Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus Sulindac Completed NCT01515137 Phase 1 Erlotinib;Erlotinib plus sulindac;Placebo
5 Biomarkers Study in Pancreatic Cancer Unknown status NCT01666184
6 Comparison of the Diagnostic Accuracy Between Base and Cover Slide Smear After Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer Completed NCT02190071
7 Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study Completed NCT01992705 Early Phase 1 -Oxaliplatin 85 mg/m2 IV on Day 1;-Irinotecan 180 mg/m2 IV on Day 1;-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
8 The Effect of a 10-day Course of Transcranial Magnetic Stimulation on Abdominal Pain in Patients With Locally Advanced and Advanced Pancreatic Cancer, a Randomized Phase II Study. Completed NCT00324428
9 A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy Recruiting NCT04281511

Search NIH Clinical Center for Pancreatic Cancer 3

Sources

Genetic Tests for Pancreatic Cancer 3

About this section

Genetic tests related to Pancreatic Cancer 3:

# Genetic test Affiliating Genes
1 Pancreatic Cancer 3 29 PALB2
Sources

Anatomical Context for Pancreatic Cancer 3

About this section

MalaCards organs/tissues related to Pancreatic Cancer 3:

40
Pancreas, Liver, Breast
Sources

Publications for Pancreatic Cancer 3

About this section

Articles related to Pancreatic Cancer 3:

(show all 21)
# Title Authors PMID Year
1
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. 6 56
19264984 2009
2
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. 56
25356972 2015
3
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. 56
17200668 2007
4
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 61
30306620 2019
5
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. 61
31230047 2019
6
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. 61
27893535 2018
7
Inferoposterior duodenal approach for laparoscopic pancreaticoduodenectomy. 61
26877619 2016
8
Inferior vena caval thrombosis complicating pyogenic liver abscess after pancreatoduodenectomy: a case report. 61
26380170 2015
9
Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies. 61
24387841 2014
10
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. 61
24419109 2014
11
Vitamin D status and the risk of pancreatic cancer: a meta-analysis. 61
24033964 2013
12
Study on chronic pancreatitis and pancreatic cancer using MRS and pancreatic juice samples. 61
21547133 2011
13
Adjuvant therapy of pancreatic cancer. 61
20397913 2010
14
Diagnosis of pancreatic cancer by cytology and telomerase activity in exfoliated cells obtained by pancreatic duct brushing during endoscopy. 61
17548257 2007
15
Serum IgG4 concentrations in pancreatic and biliary diseases. 61
16426597 2006
16
Mangan-enhanced MR imaging for the detection and localisation of small pancreatic insulinoma. 61
12955450 2004
17
Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. 61
15039161 2004
18
Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. 61
14576500 2003
19
Magnetic resonance study of the pancreatic duct. 61
10348928 1999
20
[Acute cholecystitis after placement of biliary endoprosthesis. Treatment by percutaneous cholecystostomy]. 61
2966350 1988
21
Diagnostic significance of bile cytology in obstructive jaundice. 61
6748391 1984
Sources

Variations for Pancreatic Cancer 3

About this section

ClinVar genetic disease variations for Pancreatic Cancer 3:

6 (show all 38) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PALB2 NM_024675.3(PALB2):c.106C>T (p.Gln36Ter)SNV Pathogenic 402288 rs757369748 16:23649393-23649393 16:23638072-23638072
2 PALB2 NM_024675.4(PALB2):c.1240C>T (p.Arg414Ter)SNV Pathogenic 128117 rs180177100 16:23646627-23646627 16:23635306-23635306
3 PALB2 NM_024675.3(PALB2):c.3549C>A (p.Tyr1183Ter)SNV Pathogenic 128144 rs118203998 16:23614792-23614792 16:23603471-23603471
4 PALB2 NM_024675.3(PALB2):c.2509G>T (p.Glu837Ter)SNV Pathogenic 241546 rs587778587 16:23640966-23640966 16:23629645-23629645
5 PALB2 NM_024675.3(PALB2):c.3256C>T (p.Arg1086Ter)SNV Pathogenic/Likely pathogenic 126729 rs587776527 16:23619279-23619279 16:23607958-23607958
6 PALB2 NM_024675.3(PALB2):c.2834+1G>TSNV Pathogenic/Likely pathogenic 143968 rs587776419 16:23635329-23635329 16:23624008-23624008
7 PALB2 NM_024675.4(PALB2):c.168_171TTGT[1] (p.Gln60fs)short repeat Pathogenic/Likely pathogenic 126623 rs180177143 16:23649207-23649210 16:23637886-23637889
8 PALB2 PALB2:c.2515-1G>TSNV Pathogenic/Likely pathogenic,risk factor 126657 rs587776417 16:23640597-23640597 16:23629276-23629276
9 PALB2 NM_024675.3(PALB2):c.3116del (p.Asn1039fs)deletion Pathogenic/Likely pathogenic 126715 rs180177133 16:23625410-23625410 16:23614089-23614089
10 PALB2 NM_024675.3(PALB2):c.3251C>T (p.Ser1084Leu)SNV Conflicting interpretations of pathogenicity 126727 rs62625271 16:23619284-23619284 16:23607963-23607963
11 PALB2 NM_024675.3(PALB2):c.11C>T (p.Pro4Leu)SNV Conflicting interpretations of pathogenicity 126593 rs45619737 16:23652468-23652468 16:23641147-23641147
12 PALB2 NM_024675.3(PALB2):c.2773G>C (p.Val925Leu)SNV Conflicting interpretations of pathogenicity 126681 16:23635391-23635391 16:23624070-23624070
13 PALB2 NM_024675.4(PALB2):c.3428T>A (p.Leu1143His)SNV Conflicting interpretations of pathogenicity 126740 rs62625284 16:23614913-23614913 16:23603592-23603592
14 PALB2 NM_024675.3(PALB2):c.2417C>T (p.Pro806Leu)SNV Conflicting interpretations of pathogenicity 141063 rs45464991 16:23641058-23641058 16:23629737-23629737
15 PALB2 NM_024675.3(PALB2):c.1756G>A (p.Asp586Asn)SNV Conflicting interpretations of pathogenicity 141709 rs587781954 16:23641719-23641719 16:23630398-23630398
16 PALB2 NM_024675.4(PALB2):c.194C>T (p.Pro65Leu)SNV Conflicting interpretations of pathogenicity 128124 rs62625272 16:23649188-23649188 16:23637867-23637867
17 PALB2 NM_024675.4(PALB2):c.1540G>A (p.Gly514Arg)SNV Conflicting interpretations of pathogenicity 232748 rs756778249 16:23646327-23646327 16:23635006-23635006
18 PALB2 NM_024675.3(PALB2):c.2473A>G (p.Arg825Gly)SNV Uncertain significance 402299 rs745747228 16:23641002-23641002 16:23629681-23629681
19 PALB2 NM_024675.4(PALB2):c.2897T>C (p.Ile966Thr)SNV Uncertain significance 128136 rs587780214 16:23634389-23634389 16:23623068-23623068
20 PALB2 NM_024675.3(PALB2):c.3307G>C (p.Val1103Leu)SNV Uncertain significance 141974 rs201657283 16:23619228-23619228 16:23607907-23607907
21 PALB2 NM_024675.3(PALB2):c.3428T>C (p.Leu1143Pro)SNV Uncertain significance 126741 rs62625284 16:23614913-23614913 16:23603592-23603592
22 PALB2 NM_024675.3(PALB2):c.1348A>C (p.Asn450His)SNV Uncertain significance 128119 rs62625274 16:23646519-23646519 16:23635198-23635198
23 PALB2 NM_024675.3(PALB2):c.968C>A (p.Ala323Glu)SNV Uncertain significance 182760 rs730881882 16:23646899-23646899 16:23635578-23635578
24 PALB2 NM_024675.3(PALB2):c.187C>T (p.Leu63Phe)SNV Uncertain significance 182780 rs730881899 16:23649195-23649195 16:23637874-23637874
25 PALB2 NM_024675.3(PALB2):c.1526G>A (p.Gly509Asp)SNV Uncertain significance 186732 rs786203176 16:23646341-23646341 16:23635020-23635020
26 PALB2 NM_024675.3(PALB2):c.1316G>T (p.Gly439Val)SNV Uncertain significance 188096 rs537258442 16:23646551-23646551 16:23635230-23635230
27 PALB2 NM_024675.3(PALB2):c.1115G>C (p.Ser372Thr)SNV Uncertain significance 188377 rs786204243 16:23646752-23646752 16:23635431-23635431
28 PALB2 NM_024675.3(PALB2):c.3247G>A (p.Glu1083Lys)SNV Uncertain significance 216753 rs747785029 16:23619288-23619288 16:23607967-23607967
29 PALB2 NM_024675.3(PALB2):c.1732A>G (p.Ser578Gly)SNV Uncertain significance 229738 rs764023822 16:23641743-23641743 16:23630422-23630422
30 PALB2 NM_024675.4(PALB2):c.2869A>C (p.Lys957Gln)SNV Uncertain significance 126694 rs515726103 16:23634417-23634417 16:23623096-23623096
31 PALB2 NM_024675.3(PALB2):c.1222T>C (p.Tyr408His)SNV Uncertain significance 126594 rs515726064 16:23646645-23646645 16:23635324-23635324
32 PALB2 NM_024675.3(PALB2):c.1759G>A (p.Ala587Thr)SNV Uncertain significance 410106 rs1060502733 16:23641716-23641716 16:23630395-23630395
33 PALB2 NM_024675.3(PALB2):c.3054G>T (p.Glu1018Asp)SNV Uncertain significance 420826 rs183489969 16:23632742-23632742 16:23621421-23621421
34 PALB2 NM_024675.3(PALB2):c.3025C>T (p.Pro1009Ser)SNV Uncertain significance 419928 rs764669864 16:23632771-23632771 16:23621450-23621450
35 PALB2 NM_024675.3(PALB2):c.2641G>A (p.Gly881Ser)SNV Uncertain significance 460951 rs766315705 16:23637664-23637664 16:23626343-23626343
36 PALB2 NM_024675.3(PALB2):c.2660T>G (p.Ile887Ser)SNV Uncertain significance 484201 rs45550935 16:23637645-23637645 16:23626324-23626324
37 PALB2 NM_024675.3(PALB2):c.2026A>C (p.Ile676Leu)SNV Uncertain significance 484244 rs761478794 16:23641449-23641449 16:23630128-23630128
38 PALB2 NM_024675.3(PALB2):c.1340C>A (p.Ala447Glu)SNV Uncertain significance 480285 rs1555461334 16:23646527-23646527 16:23635206-23635206
Sources

Expression for Pancreatic Cancer 3

About this section
Search GEO for disease gene expression data for Pancreatic Cancer 3.
Sources

Pathways for Pancreatic Cancer 3

About this section
Sources

GO Terms for Pancreatic Cancer 3

About this section
Sources

Sources for Pancreatic Cancer 3

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....